Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

. Author manuscript; available in PMC: 2022 Dec 1.

Published in final edited form as: Lancet Oncol. 2021 Nov 10;22(12):1692–1704. doi: 10.1016/S1470-2045(21)00545-3

Figure 1: Kaplan-Meier estimates of investigator-assessed progression-free survival (A), BICR-assessed progression-free survival (B), and overall survival (C) in patients with asymptomatic melanoma brain metastases.